skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A danger of induction of Brugada syndrome during pill-in-the-pocket therapy for paroxysmal atrial fibrillation

Case report

(2002) Views  (455) Full article downloads

Authors: Yoshiyasu Aizawa, Tomohiro Matsuhashi, Toshiaki Sato, et al

Published Date August 2010 Volume 2010:2 Pages 139 - 140
DOI: http://dx.doi.org/10.2147/DHPS.S12491

Yoshiyasu Aizawa, Tomohiro Matsuhashi, Toshiaki Sato, Seiji Takatsuki, Keiichi Fukuda
Division of Cardiology, Keio University School of Medicine, Tokyo, Japan

Abstract: Rhythm control therapy by sodium channel blockers is widely performed for the ­treatment of paroxysmal atrial fibrillation. Here, we present a case of acquired Brugada ­syndrome by pill-in-the-pocket treatment using pilsicainide. It is important that this therapy should be applied only after confirming the drug safety to the patients.

Keywords: syncope, sudden death, drug, rhythm control, pilsicainide, atrial flutter








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Antidepressant-associated sexual dysfunction: impact, effects, and treatment
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio